Robert J. Ferrante, PhD - Publications

Affiliations: 
Neurology, Pathology, & Psychiatry Boston University, Boston, MA, United States 
Area:
http://www.biomedexperts.com/Profile.bme/395895/Robert_J_Ferrante
Website:
http://www.bu.edu/alzresearch/team/faculty/ferrante.html

155 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Tourette C, Farina F, Vazquez-Manrique RP, Orfila AM, Voisin J, Hernandez S, Offner N, Parker JA, Menet S, Kim J, Lyu J, Choi SH, Cormier K, Edgerly CK, Bordiuk OL, ... ... Ferrante RJ, et al. The Wnt receptor Ryk reduces neuronal and cell survival capacity by repressing FOXO activity during the early phases of mutant huntingtin pathogenicity. Plos Biology. 12: e1001895. PMID 24960609 DOI: 10.1371/journal.pbio.1001895  0.6
2014 Yano H, Baranov SV, Baranova OV, Kim J, Pan Y, Yablonska S, Carlisle DL, Ferrante RJ, Kim AH, Friedlander RM. Inhibition of mitochondrial protein import by mutant huntingtin. Nature Neuroscience. 17: 822-31. PMID 24836077 DOI: 10.1038/nn.3721  0.6
2013 Zhang Y, Cook A, Kim J, Baranov SV, Jiang J, Smith K, Cormier K, Bennett E, Browser RP, Day AL, Carlisle DL, Ferrante RJ, Wang X, Friedlander RM. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiology of Disease. 55: 26-35. PMID 23537713 DOI: 10.1016/j.nbd.2013.03.008  0.6
2013 Taylor DM, Moser R, Régulier E, Breuillaud L, Dixon M, Beesen AA, Elliston L, Silva Santos Mde F, Kim J, Jones L, Goldstein DR, Ferrante RJ, Luthi-Carter R. MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 33: 2313-25. PMID 23392662 DOI: 10.1523/JNEUROSCI.4965-11.2013  0.6
2012 Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, Edgerly C, Cipicchio PM, Lauver MA, Choi SH, Silverman RB, Ferrante RJ, Hersch S, Kazantsev AG. The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Reports. 2: 1492-7. PMID 23200855 DOI: 10.1016/j.celrep.2012.11.001  0.6
2012 Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, Crystal RG, Darnell RB, Ferrante RJ, Fillit H, Finkelstein R, Fisher M, Gendelman HE, Golub RM, Goudreau JL, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 490: 187-91. PMID 23060188 DOI: 10.1038/nature11556  0.6
2012 Zhang Y, Benmohamed R, Zhang W, Kim J, Edgerly CK, Zhu Y, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB. Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS. Acs Medicinal Chemistry Letters. 3: 584-587. PMID 22837812 DOI: 10.1021/ml3000963  0.6
2012 Wright PD, Wightman N, Huang M, Weiss A, Sapp PC, Cuny GD, Ivinson AJ, Glicksman MA, Ferrante RJ, Matson W, Matson S, Brown RH. A high-throughput screen to identify inhibitors of SOD1 transcription. Frontiers in Bioscience (Elite Edition). 4: 2801-8. PMID 22652679  0.6
2012 Chen T, Benmohamed R, Kim J, Smith K, Amante D, Morimoto RI, Kirsch DR, Ferrante RJ, Silverman RB. ADME-guided design and synthesis of aryloxanyl pyrazolone derivatives to block mutant superoxide dismutase 1 (SOD1) cytotoxicity and protein aggregation: potential application for the treatment of amyotrophic lateral sclerosis. Journal of Medicinal Chemistry. 55: 515-27. PMID 22191331 DOI: 10.1021/jm2014277  0.6
2012 Zhang W, Benmohamed R, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB. Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. Bioorganic & Medicinal Chemistry. 20: 1029-45. PMID 22189273 DOI: 10.1016/j.bmc.2011.11.039  0.6
2011 Wang X, Sirianni A, Pei Z, Cormier K, Smith K, Jiang J, Zhou S, Wang H, Zhao R, Yano H, Kim JE, Li W, Kristal BS, Ferrante RJ, Friedlander RM. The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 14496-507. PMID 21994366 DOI: 10.1523/JNEUROSCI.3059-11.2011  0.6
2011 Keryer G, Pineda JR, Liot G, Kim J, Dietrich P, Benstaali C, Smith K, Cordelières FP, Spassky N, Ferrante RJ, Dragatsis I, Saudou F. Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. The Journal of Clinical Investigation. 121: 4372-82. PMID 21985783 DOI: 10.1172/JCI57552  0.6
2011 Hu Y, Chopra V, Chopra R, Locascio JJ, Liao Z, Ding H, Zheng B, Matson WR, Ferrante RJ, Rosas HD, Hersch SM, Scherzer CR. Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proceedings of the National Academy of Sciences of the United States of America. 108: 17141-6. PMID 21969577 DOI: 10.1073/pnas.1104409108  0.6
2011 Kim J, Bordiuk OL, Ferrante RJ. Experimental models of HD and reflection on therapeutic strategies. International Review of Neurobiology. 98: 419-81. PMID 21907096 DOI: 10.1016/B978-0-12-381328-2.00016-X  0.6
2011 Xia G, Benmohamed R, Kim J, Arvanites AC, Morimoto RI, Ferrante RJ, Kirsch DR, Silverman RB. Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. Journal of Medicinal Chemistry. 54: 2409-21. PMID 21375347 DOI: 10.1021/jm101549k  0.6
2011 Chen T, Benmohamed R, Arvanites AC, Ralay Ranaivo H, Morimoto RI, Ferrante RJ, Watterson DM, Kirsch DR, Silverman RB. Arylsulfanyl pyrazolones block mutant SOD1-G93A aggregation. Potential application for the treatment of amyotrophic lateral sclerosis. Bioorganic & Medicinal Chemistry. 19: 613-22. PMID 21095130 DOI: 10.1016/j.bmc.2010.10.052  0.6
2011 Benmohamed R, Arvanites AC, Kim J, Ferrante RJ, Silverman RB, Morimoto RI, Kirsch DR. Identification of compounds protective against G93A-SOD1 toxicity for the treatment of amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 12: 87-96. PMID 21073276 DOI: 10.3109/17482968.2010.522586  0.6
2010 Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, et al. Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1924-8. PMID 20669312 DOI: 10.1002/mds.22408  0.6
2010 Kim J, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Beal MF, Ferrante RJ. Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Human Molecular Genetics. 19: 3919-35. PMID 20660112 DOI: 10.1093/hmg/ddq306  0.6
2010 Amante DJ, Kim J, Carreiro ST, Cooper AC, Jones SW, Li T, Moody JP, Edgerly CK, Bordiuk OL, Cormier K, Smith K, Ferrante RJ, Rusche J. Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 11: 520-30. PMID 20565334 DOI: 10.3109/17482968.2010.491867  0.6
2010 Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N, Guillermier M, Brouillet E, Hantraye P, Déglon N, Ferrante RJ, Bonvento G. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Human Molecular Genetics. 19: 3053-67. PMID 20494921 DOI: 10.1093/hmg/ddq212  0.6
2010 Kim J, Amante DJ, Moody JP, Edgerly CK, Bordiuk OL, Smith K, Matson SA, Matson WR, Scherzer CR, Rosas HD, Hersch SM, Ferrante RJ. Reduced creatine kinase as a central and peripheral biomarker in Huntington's disease. Biochimica Et Biophysica Acta. 1802: 673-81. PMID 20460152 DOI: 10.1016/j.bbadis.2010.05.001  0.6
2009 Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. Journal of Neurochemistry. 109: 1427-39. PMID 19476553 DOI: 10.1111/j.1471-4159.2009.06074.x  0.6
2009 Ferrante RJ. Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochimica Et Biophysica Acta. 1792: 506-20. PMID 19362590 DOI: 10.1016/j.bbadis.2009.04.001  0.6
2009 Noh JY, Lee H, Song S, Kim NS, Im W, Kim M, Seo H, Chung CW, Chang JW, Ferrante RJ, Yoo YJ, Ryu H, Jung YK. SCAMP5 links endoplasmic reticulum stress to the accumulation of expanded polyglutamine protein aggregates via endocytosis inhibition. The Journal of Biological Chemistry. 284: 11318-25. PMID 19240033 DOI: 10.1074/jbc.M807620200  0.6
2009 Lee J, Kannagi M, Ferrante RJ, Kowall NW, Ryu H. Activation of Ets-2 by oxidative stress induces Bcl-xL expression and accounts for glial survival in amyotrophic lateral sclerosis. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 23: 1739-49. PMID 19179380 DOI: 10.1096/fj.08-121046  0.6
2009 Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ. Phase 2 study of sodium phenylbutyrate in ALS. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 10: 99-106. PMID 18688762 DOI: 10.1080/17482960802320487  0.6
2009 Del Signore SJ, Amante DJ, Kim J, Stack EC, Goodrich S, Cormier K, Smith K, Cudkowicz ME, Ferrante RJ. Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice. Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group On Motor Neuron Diseases. 10: 85-94. PMID 18618304 DOI: 10.1080/17482960802226148  0.6
2008 Stack EC, Matson WR, Ferrante RJ. Evidence of oxidant damage in Huntington's disease: translational strategies using antioxidants. Annals of the New York Academy of Sciences. 1147: 79-92. PMID 19076433 DOI: 10.1196/annals.1427.008  0.6
2008 Wang X, Zhu S, Pei Z, Drozda M, Stavrovskaya IG, Del Signore SJ, Cormier K, Shimony EM, Wang H, Ferrante RJ, Kristal BS, Friedlander RM. Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 9473-85. PMID 18799679 DOI: 10.1523/JNEUROSCI.1867-08.2008  0.6
2008 Lee J, Hagerty S, Cormier KA, Kim J, Kung AL, Ferrante RJ, Ryu H. Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. Human Molecular Genetics. 17: 1774-82. PMID 18319327 DOI: 10.1093/hmg/ddn067  0.6
2008 Stack EC, Ferro JL, Kim J, Del Signore SJ, Goodrich S, Matson S, Hunt BB, Cormier K, Smith K, Matson WR, Ryu H, Ferrante RJ. Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochimica Et Biophysica Acta. 1782: 151-62. PMID 18206128 DOI: 10.1016/j.bbadis.2007.12.006  0.6
2008 Lee J, Sharma S, Kim J, Ferrante RJ, Ryu H. Mitochondrial nuclear receptors and transcription factors: who's minding the cell? Journal of Neuroscience Research. 86: 961-71. PMID 18041090 DOI: 10.1002/jnr.21564  0.6
2007 Klein AM, Ferrante RJ. The neuroprotective role of creatine. Sub-Cellular Biochemistry. 46: 205-43. PMID 18652079  0.6
2007 Stack EC, Ferrante RJ. Huntington's disease: progress and potential in the field. Expert Opinion On Investigational Drugs. 16: 1933-53. PMID 18042002 DOI: 10.1517/13543784.16.12.1933  0.6
2007 Stack EC, Dedeoglu A, Smith KM, Cormier K, Kubilus JK, Bogdanov M, Matson WR, Yang L, Jenkins BG, Luthi-Carter R, Kowall NW, Hersch SM, Beal MF, Ferrante RJ. Neuroprotective effects of synaptic modulation in Huntington's disease R6/2 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 12908-15. PMID 18032664 DOI: 10.1523/JNEUROSCI.4318-07.2007  0.6
2007 Wang H, Guan Y, Wang X, Smith K, Cormier K, Zhu S, Stavrovskaya IG, Huo C, Ferrante RJ, Kristal BS, Friedlander RM. Nortriptyline delays disease onset in models of chronic neurodegeneration. The European Journal of Neuroscience. 26: 633-41. PMID 17686041 DOI: 10.1111/j.1460-9568.2007.05663.x  0.6
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/hmg/ddm133  0.6
2007 Huang QY, Yu L, Ferrante RJ, Chen JF. Mutant SOD1G93A in bone marrow-derived cells exacerbates 3-nitropropionic acid induced striatal damage in mice. Neuroscience Letters. 418: 175-80. PMID 17418947 DOI: 10.1016/j.neulet.2007.03.038  0.6
2007 Stack EC, Del Signore SJ, Luthi-Carter R, Soh BY, Goldstein DR, Matson S, Goodrich S, Markey AL, Cormier K, Hagerty SW, Smith K, Ryu H, Ferrante RJ. Modulation of nucleosome dynamics in Huntington's disease. Human Molecular Genetics. 16: 1164-75. PMID 17403718 DOI: 10.1093/hmg/ddm064  0.6
2007 Ryu H, Ferrante RJ. Translational therapeutic strategies in amyotrophic lateral sclerosis. Mini Reviews in Medicinal Chemistry. 7: 141-50. PMID 17305588 DOI: 10.2174/138955707779802570  0.6
2007 Moretto N, Bolchi A, Rivetti C, Imbimbo BP, Villetti G, Pietrini V, Polonelli L, Del Signore S, Smith KM, Ferrante RJ, Ottonello S. Conformation-sensitive antibodies against alzheimer amyloid-beta by immunization with a thioredoxin-constrained B-cell epitope peptide. The Journal of Biological Chemistry. 282: 11436-45. PMID 17267402 DOI: 10.1074/jbc.M609690200  0.6
2006 Ryu H, Lee J, Hagerty SW, Soh BY, McAlpin SE, Cormier KA, Smith KM, Ferrante RJ. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 103: 19176-81. PMID 17142323 DOI: 10.1073/pnas.0606373103  0.6
2006 Lee J, Kosaras B, Aleyasin H, Han JA, Park DS, Ratan RR, Kowall NW, Ferrante RJ, Lee SW, Ryu H. Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 2375-7. PMID 17012241 DOI: 10.1096/fj.06-5957fje  0.6
2006 Smith KM, Matson S, Matson WR, Cormier K, Del Signore SJ, Hagerty SW, Stack EC, Ryu H, Ferrante RJ. Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochimica Et Biophysica Acta. 1762: 616-26. PMID 16647250 DOI: 10.1016/j.bbadis.2006.03.004  0.6
2006 Qiu Z, Norflus F, Singh B, Swindell MK, Buzescu R, Bejarano M, Chopra R, Zucker B, Benn CL, DiRocco DP, Cha JH, Ferrante RJ, Hersch SM. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. The Journal of Biological Chemistry. 281: 16672-80. PMID 16595660 DOI: 10.1074/jbc.M511648200  0.6
2006 Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW, Del Signore SJ, Cudkowicz ME, Friedlander RM, Ferrante RJ. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochimica Et Biophysica Acta. 1762: 373-80. PMID 16364609 DOI: 10.1016/j.bbadis.2005.11.002  0.6
2006 Klivenyi P, Siwek D, Gardian G, Yang L, Starkov A, Cleren C, Ferrante RJ, Kowall NW, Abeliovich A, Beal MF. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease. 21: 541-8. PMID 16298531 DOI: 10.1016/j.nbd.2005.08.018  0.6
2005 Lee J, Kim CH, Simon DK, Aminova LR, Andreyev AY, Kushnareva YE, Murphy AN, Lonze BE, Kim KS, Ginty DD, Ferrante RJ, Ryu H, Ratan RR. Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. The Journal of Biological Chemistry. 280: 40398-401. PMID 16207717 DOI: 10.1074/jbc.C500140200  0.6
2005 Ryu H, Lee J, Impey S, Ratan RR, Ferrante RJ. Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proceedings of the National Academy of Sciences of the United States of America. 102: 13915-20. PMID 16169904 DOI: 10.1073/pnas.0502878102  0.6
2005 Jenkins BG, Andreassen OA, Dedeoglu A, Leavitt B, Hayden M, Borchelt D, Ross CA, Ferrante RJ, Beal MF. Effects of CAG repeat length, HTT protein length and protein context on cerebral metabolism measured using magnetic resonance spectroscopy in transgenic mouse models of Huntington's disease. Journal of Neurochemistry. 95: 553-62. PMID 16135087 DOI: 10.1111/j.1471-4159.2005.03411.x  0.6
2005 Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, Hersch SM, Ferrante RJ. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. The Journal of Comparative Neurology. 490: 354-70. PMID 16127709 DOI: 10.1002/cne.20680  0.6
2005 Ryu H, Rosas HD, Hersch SM, Ferrante RJ. The therapeutic role of creatine in Huntington's disease. Pharmacology & Therapeutics. 108: 193-207. PMID 16055197 DOI: 10.1016/j.pharmthera.2005.04.008  0.6
2005 Ryu H, Smith K, Camelo SI, Carreras I, Lee J, Iglesias AH, Dangond F, Cormier KA, Cudkowicz ME, Brown RH, Ferrante RJ. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry. 93: 1087-98. PMID 15934930 DOI: 10.1111/j.1471-4159.2005.03077.x  0.6
2005 Ryu H, Ferrante RJ. Emerging chemotherapeutic strategies for Huntington's disease. Expert Opinion On Emerging Drugs. 10: 345-63. PMID 15934871 DOI: 10.1517/14728214.10.2.345  0.6
2005 Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, ... Ferrante RJ, et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroimmunology. 164: 10-21. PMID 15885809 DOI: 10.1016/j.jneuroim.2005.02.022  0.6
2005 Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. The Journal of Biological Chemistry. 280: 556-63. PMID 15494404 DOI: 10.1074/jbc.M410210200  0.6
2004 Hersch SM, Ferrante RJ. Translating therapies for Huntington's disease from genetic animal models to clinical trials. Neurorx : the Journal of the American Society For Experimental Neurotherapeutics. 1: 298-306. PMID 15717031 DOI: 10.1602/neurorx.1.3.298  0.6
2004 Ferrante RJ, Ryu H, Kubilus JK, D'Mello S, Sugars KL, Lee J, Lu P, Smith K, Browne S, Beal MF, Kristal BS, Stavrovskaya IG, Hewett S, Rubinsztein DC, Langley B, et al. Chemotherapy for the brain: the antitumor antibiotic mithramycin prolongs survival in a mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 10335-42. PMID 15548647 DOI: 10.1523/JNEUROSCI.2599-04.2004  0.6
2004 Norflus F, Nanje A, Gutekunst CA, Shi G, Cohen J, Bejarano M, Fox J, Ferrante RJ, Hersch SM. Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiology of Disease. 17: 319-25. PMID 15474369 DOI: 10.1016/j.nbd.2004.07.011  0.6
2004 Fox JH, Barber DS, Singh B, Zucker B, Swindell MK, Norflus F, Buzescu R, Chopra R, Ferrante RJ, Kazantsev A, Hersch SM. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. Journal of Neurochemistry. 91: 413-22. PMID 15447674 DOI: 10.1111/j.1471-4159.2004.02726.x  0.6
2004 Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, Brown RH, Kristal BS, Ferrante RJ, Friedlander RM. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 5909-12. PMID 15229238 DOI: 10.1523/JNEUROSCI.1278-04.2004  0.6
2004 Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nature Reviews. Neuroscience. 5: 373-84. PMID 15100720 DOI: 10.1038/nrn1386  0.6
2004 Fink JS, Kalda A, Ryu H, Stack EC, Schwarzschild MA, Chen JF, Ferrante RJ. Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. Journal of Neurochemistry. 88: 538-44. PMID 14720203 DOI: 10.1046/j.1471-4159.2003.02145.x  0.6
2003 Andreassen OA, Ferrante RJ, Aamo TO, Beal MF, Jørgensen HA. Oral dyskinesias and histopathological alterations in substantia nigra after long-term haloperidol treatment of old rats. Neuroscience. 122: 717-25. PMID 14622915 DOI: 10.1016/j.neuroscience.2003.08.058  0.6
2003 Zhang Y, Ona VO, Li M, Drozda M, Dubois-Dauphin M, Przedborski S, Ferrante RJ, Friedlander RM. Sequential activation of individual caspases, and of alterations in Bcl-2 proapoptotic signals in a mouse model of Huntington's disease. Journal of Neurochemistry. 87: 1184-92. PMID 14622098 DOI: 10.1046/j.1471-4159.2003.02105.x  0.6
2003 Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 9418-27. PMID 14561870  0.6
2003 Clement AM, Nguyen MD, Roberts EA, Garcia ML, Boillée S, Rule M, McMahon AP, Doucette W, Siwek D, Ferrante RJ, Brown RH, Julien JP, Goldstein LS, Cleveland DW. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (New York, N.Y.). 302: 113-7. PMID 14526083 DOI: 10.1126/science.1086071  0.6
2003 Zhang Y, Li M, Drozda M, Chen M, Ren S, Mejia Sanchez RO, Leavitt BR, Cattaneo E, Ferrante RJ, Hayden MR, Friedlander RM. Depletion of wild-type huntingtin in mouse models of neurologic diseases. Journal of Neurochemistry. 87: 101-6. PMID 12969257 DOI: 10.1046/j.1471-4159.2003.01980.x  0.6
2003 Wang X, Zhu S, Drozda M, Zhang W, Stavrovskaya IG, Cattaneo E, Ferrante RJ, Kristal BS, Friedlander RM. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 10483-7. PMID 12930891 DOI: 10.1073/pnas.1832501100  0.6
2003 Blackshaw S, Eliasson MJ, Sawa A, Watkins CC, Krug D, Gupta A, Arai T, Ferrante RJ, Snyder SH. Species, strain and developmental variations in hippocampal neuronal and endothelial nitric oxide synthase clarify discrepancies in nitric oxide-dependent synaptic plasticity. Neuroscience. 119: 979-90. PMID 12831857 DOI: 10.1016/S0306-4522(03)00217-3  0.6
2003 Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 86: 267-72. PMID 12807446 DOI: 10.1046/j.1471-4159.2003.t01-1-01868.x  0.6
2003 Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. Journal of Neurochemistry. 85: 1359-67. PMID 12787055 DOI: 10.1046/j.1471-4159.2003.01706.x  0.6
2003 Ryu H, Lee J, Zaman K, Kubilis J, Ferrante RJ, Ross BD, Neve R, Ratan RR. Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 3597-606. PMID 12736330  0.6
2003 Lee J, Ryu H, Ferrante RJ, Morris SM, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proceedings of the National Academy of Sciences of the United States of America. 100: 4843-8. PMID 12655043 DOI: 10.1073/pnas.0735876100  0.6
2003 Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ratan RR, Deodoglu A. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proceedings of the National Academy of Sciences of the United States of America. 100: 4281-6. PMID 12640146 DOI: 10.1073/pnas.0737363100  0.6
2003 Holbert S, Dedeoglu A, Humbert S, Saudou F, Ferrante RJ, Néri C. Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 2712-7. PMID 12604778 DOI: 10.1073/pnas.0437967100  0.6
2002 Andreassen OA, Dedeoglu A, Stanojevic V, Hughes DB, Browne SE, Leech CA, Ferrante RJ, Habener JF, Beal MF, Thomas MK. Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiology of Disease. 11: 410-24. PMID 12586550 DOI: 10.1006/nbdi.2002.0562  0.6
2002 Dedeoglu A, Kubilus JK, Jeitner TM, Matson SA, Bogdanov M, Kowall NW, Matson WR, Cooper AJ, Ratan RR, Beal MF, Hersch SM, Ferrante RJ. Therapeutic effects of cystamine in a murine model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 8942-50. PMID 12388601  0.6
2002 Kiechle T, Dedeoglu A, Kubilus J, Kowall NW, Beal MF, Friedlander RM, Hersch SM, Ferrante RJ. Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecular Medicine. 1: 183-95. PMID 12095160 DOI: 10.1385/NMM:1:3:183  0.6
2002 Dedeoglu A, Ferrante RJ, Andreassen OA, Dillmann WH, Beal MF. Mice overexpressing 70-kDa heat shock protein show increased resistance to malonate and 3-nitropropionic acid. Experimental Neurology. 176: 262-5. PMID 12093104 DOI: 10.1006/exnr.2002.7933  0.6
2002 Zhu S, Stavrovskaya IG, Drozda M, Kim BY, Ona V, Li M, Sarang S, Liu AS, Hartley DM, Wu DC, Gullans S, Ferrante RJ, Przedborski S, Kristal BS, Friedlander RM. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 417: 74-8. PMID 11986668 DOI: 10.1038/417074a  0.6
2002 Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischl B. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology. 58: 695-701. PMID 11889230  0.6
2002 Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM, Beal MF. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 1592-9. PMID 11880489  0.6
2001 Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF. Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. Journal of Neurochemistry. 79: 1246-9. PMID 11752065 DOI: 10.1046/j.1471-4159.2001.00689.x  0.6
2001 Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport. 12: 3371-3. PMID 11711888  0.6
2001 Ferrante RJ, Klein AM, Dedeoglu A, Beal MF. Therapeutic efficacy of EGb761 (Gingko biloba extract) in a transgenic mouse model of amyotrophic lateral sclerosis. Journal of Molecular Neuroscience : Mn. 17: 89-96. PMID 11665866 DOI: 10.1385/JMN:17:1:89  0.6
2001 Andreassen OA, Ferrante RJ, Huang HM, Dedeoglu A, Park L, Ferrante KL, Kwon J, Borchelt DR, Ross CA, Gibson GE, Beal MF. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Annals of Neurology. 50: 112-7. PMID 11456300 DOI: 10.1002/ana.1085  0.6
2001 Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiology of Disease. 8: 479-91. PMID 11447996 DOI: 10.1006/nbdi.2001.0406  0.6
2001 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Dedeoglu A, Albers DS, Kowall NW, Beal MF. Transgenic ALS mice show increased vulnerability to the mitochondrial toxins MPTP and 3-nitropropionic acid. Experimental Neurology. 168: 356-63. PMID 11259123 DOI: 10.1006/exnr.2001.7627  0.6
2001 Holbert S, Denghien I, Kiechle T, Rosenblatt A, Wellington C, Hayden MR, Margolis RL, Ross CA, Dausset J, Ferrante RJ, Néri C. The Gln-Ala repeat transcriptional activator CA150 interacts with huntingtin: neuropathologic and genetic evidence for a role in Huntington's disease pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 98: 1811-6. PMID 11172033 DOI: 10.1073/pnas.041566798  0.6
2001 Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, Carlson EJ, Epstein CJ, Beal MF. Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP. Experimental Neurology. 167: 189-95. PMID 11161607 DOI: 10.1006/exnr.2000.7525  0.6
2000 Andreassen OA, Ferrante RJ, Hughes DB, Klivenyi P, Dedeoglu A, Ona VO, Friedlander RM, Beal MF. Malonate and 3-nitropropionic acid neurotoxicity are reduced in transgenic mice expressing a caspase-1 dominant-negative mutant. Journal of Neurochemistry. 75: 847-52. PMID 10899963 DOI: 10.1046/j.1471-4159.2000.0750847.x  0.6
2000 Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nature Medicine. 6: 797-801. PMID 10888929 DOI: 10.1038/77528  0.6
2000 Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, Kaddurah-Daouk R, Hersch SM, Beal MF. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 4389-97. PMID 10844007  0.6
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Lancelot E, Reif D, Beal MF. Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity. Neuroreport. 11: 1265-8. PMID 10817604  0.6
2000 Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. Journal of Neurochemistry. 74: 2108-19. PMID 10800956 DOI: 10.1046/j.1471-4159.2000.0742108.x  0.6
2000 Andreassen OA, Ferrante RJ, Klivenyi P, Klein AM, Shinobu LA, Epstein CJ, Beal MF. Partial deficiency of manganese superoxide dismutase exacerbates a transgenic mouse model of amyotrophic lateral sclerosis. Annals of Neurology. 47: 447-55. PMID 10762155 DOI: 10.1002/1531-8249(200004)47:4<447::AID-ANA7>3.0.CO;2-R  0.6
2000 Kowall NW, Hantraye P, Brouillet E, Beal MF, McKee AC, Ferrante RJ. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport. 11: 211-3. PMID 10683860  0.6
2000 Klivenyi P, Andreassen OA, Ferrante RJ, Dedeoglu A, Mueller G, Lancelot E, Bogdanov M, Andersen JK, Jiang D, Beal MF. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate, 3-nitropropionic acid, and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 1-7. PMID 10627575  0.6
1999 Klein AM, Kowall NW, Ferrante RJ. Neurotoxicity and oxidative damage of beta amyloid 1-42 versus beta amyloid 1-40 in the mouse cerebral cortex. Annals of the New York Academy of Sciences. 893: 314-20. PMID 10672257  0.6
1999 Kuemmerle S, Gutekunst CA, Klein AM, Li XJ, Li SH, Beal MF, Hersch SM, Ferrante RJ. Huntington aggregates may not predict neuronal death in Huntington's disease. Annals of Neurology. 46: 842-9. PMID 10589536 DOI: 10.1002/1531-8249(199912)46:6<842::AID-ANA6>3.0.CO;2-O  0.6
1999 Lesort M, Chun W, Johnson GV, Ferrante RJ. Tissue transglutaminase is increased in Huntington's disease brain. Journal of Neurochemistry. 73: 2018-27. PMID 10537061  0.6
1999 Shefner JM, Reaume AG, Flood DG, Scott RW, Kowall NW, Ferrante RJ, Siwek DF, Upton-Rice M, Brown RH. Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy. Neurology. 53: 1239-46. PMID 10522879  0.6
1999 Hanlon EB, Itzkan I, Dasari RR, Feld MS, Ferrante RJ, McKee AC, Lathi D, Kowall NW. Near-infrared fluorescence spectroscopy detects Alzheimer's disease in vitro. Photochemistry and Photobiology. 70: 236-42. PMID 10461462  0.6
1999 Eliasson MJ, Huang Z, Ferrante RJ, Sasamata M, Molliver ME, Snyder SH, Moskowitz MA. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischemic stroke linked to neural damage. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 5910-8. PMID 10407030  0.6
1999 Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Experimental Neurology. 157: 142-9. PMID 10222117 DOI: 10.1006/exnr.1999.7049  0.6
1999 Klevenyi P, Andreassen O, Ferrante RJ, Schleicher JR, Friedlander RM, Beal MF. Transgenic mice expressing a dominant negative mutant interleukin-1beta converting enzyme show resistance to MPTP neurotoxicity. Neuroreport. 10: 635-8. PMID 10208603  0.6
1999 Ferrante RJ, Hantraye P, Brouillet E, Beal MF. Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Research. 823: 177-82. PMID 10095024 DOI: 10.1016/S0006-8993(99)01166-X  0.6
1999 Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 2522-34. PMID 10087066  0.6
1999 Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 5: 347-50. PMID 10086395 DOI: 10.1038/6568  0.6
1999 Bogdanov MB, Ferrante RJ, Mueller G, Ramos LE, Martinou JC, Beal MF. Oxidative stress is attenuated in mice overexpressing BCL-2. Neuroscience Letters. 262: 33-6. PMID 10076866 DOI: 10.1016/S0304-3940(99)00047-6  0.6
1999 Browne SE, Ferrante RJ, Beal MF. Oxidative stress in Huntington's disease. Brain Pathology (Zurich, Switzerland). 9: 147-63. PMID 9989457  0.76
1998 Bogdanov MB, Ferrante RJ, Kuemmerle S, Klivenyi P, Beal MF. Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington's disease. Journal of Neurochemistry. 71: 2642-4. PMID 9832167  0.6
1998 Klivenyi P, Beal MF, Ferrante RJ, Andreassen OA, Wermer M, Chin MR, Bonventre JV. Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity. Journal of Neurochemistry. 71: 2634-7. PMID 9832165  0.6
1998 Andreassen OA, Ferrante RJ, Beal MF, Jørgensen HA. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Neuroscience. 87: 639-48. PMID 9758230  0.76
1998 Gutekunst CA, Li SH, Yi H, Ferrante RJ, Li XJ, Hersch SM. The cellular and subcellular localization of huntingtin-associated protein 1 (HAP1): comparison with huntingtin in rat and human. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 7674-86. PMID 9742138  0.6
1998 Li SH, Hosseini SH, Gutekunst CA, Hersch SM, Ferrante RJ, Li XJ. A human HAP1 homologue. Cloning, expression, and interaction with huntingtin. The Journal of Biological Chemistry. 273: 19220-7. PMID 9668110 DOI: 10.1074/jbc.273.30.19220  0.6
1998 Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 156-63. PMID 9412496  0.6
1997 Beal MF, Ferrante RJ, Browne SE, Matthews RT, Kowall NW, Brown RH. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Annals of Neurology. 42: 644-54. PMID 9382477 DOI: 10.1002/ana.410420416  0.6
1997 Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH, Beal MF. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. Journal of Neurochemistry. 69: 2064-74. PMID 9349552  0.6
1997 Ferrante RJ, Shinobu LA, Schulz JB, Matthews RT, Thomas CE, Kowall NW, Gurney ME, Beal MF. Increased 3-nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Annals of Neurology. 42: 326-34. PMID 9307254 DOI: 10.1002/ana.410420309  0.6
1997 Ayata C, Ayata G, Hara H, Matthews RT, Beal MF, Ferrante RJ, Endres M, Kim A, Christie RH, Waeber C, Huang PL, Hyman BT, Moskowitz MA. Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 6908-17. PMID 9278526  0.6
1997 Matthews RT, Ferrante RJ, Jenkins BG, Browne SE, Goetz K, Berger S, Chen IY, Beal MF. Iodoacetate produces striatal excitotoxic lesions. Journal of Neurochemistry. 69: 285-9. PMID 9202321  0.6
1997 Ferrante RJ, Schulz JB, Kowall NW, Beal MF. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Research. 753: 157-62. PMID 9125443  1
1997 Ferrante RJ, Gutekunst CA, Persichetti F, McNeil SM, Kowall NW, Gusella JF, MacDonald ME, Beal MF, Hersch SM. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 17: 3052-63. PMID 9096140  0.6
1996 Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH, Scott RW, Snider WD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nature Genetics. 13: 43-7. PMID 8673102 DOI: 10.1038/ng0596-43  0.6
1996 Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P. Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 16: 3019-25. PMID 8622131  0.6
1995 Schulz JB, Matthews RT, Jenkins BG, Ferrante RJ, Siwek D, Henshaw DR, Cipolloni PB, Mecocci P, Kowall NW, Rosen BR. Blockade of neuronal nitric oxide synthase protects against excitotoxicity in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 15: 8419-29. PMID 8613773  0.6
1995 Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proceedings of the National Academy of Sciences of the United States of America. 92: 7105-9. PMID 7624378 DOI: 10.1073/pnas.92.15.7105  0.6
1995 Beal MF, Ferrante RJ, Henshaw R, Matthews RT, Chan PH, Kowall NW, Epstein CJ, Schulz JB. 3-Nitropropionic acid neurotoxicity is attenuated in copper/zinc superoxide dismutase transgenic mice. Journal of Neurochemistry. 65: 919-22. PMID 7616254  0.6
1995 Schulz JB, Henshaw DR, Siwek D, Jenkins BG, Ferrante RJ, Cipolloni PB, Kowall NW, Rosen BR, Beal MF. Involvement of free radicals in excitotoxicity in vivo. Journal of Neurochemistry. 64: 2239-47. PMID 7536809  0.6
1994 Henshaw R, Jenkins BG, Schulz JB, Ferrante RJ, Kowall NW, Rosen BR, Beal MF. Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Research. 647: 161-6. PMID 8069700  1
1994 Rosen DR, Bowling AC, Patterson D, Usdin TB, Sapp P, Mezey E, McKenna-Yasek D, O'Regan J, Rahmani Z, Ferrante RJ. A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis. Human Molecular Genetics. 3: 981-7. PMID 7951249  0.6
1994 Schulz JB, Henshaw DR, Jenkins BG, Ferrante RJ, Kowall NW, Rosen BR, Beal MF. 3-Acetylpyridine produces age-dependent excitotoxic lesions in rat striatum. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 14: 1024-9. PMID 7929644 DOI: 10.1038/jcbfm.1994.134  1
1994 Storey E, Cipolloni PB, Ferrante RJ, Kowall NW, Beal MF. Movement disorder following excitotoxin lesions in primates. Neuroreport. 5: 1259-61. PMID 7919178  1
1993 Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Experimental Neurology. 119: 46-71. PMID 8432351 DOI: 10.1006/exnr.1993.1006  1
1993 Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, Beal MF. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. Journal of Neurochemistry. 60: 356-9. PMID 8417157  0.6
1993 Kowall NW, Quigley BJ, Krause JE, Lu F, Kosofsky BE, Ferrante RJ. Substance P and substance P receptor histochemistry in human neurodegenerative diseases. Regulatory Peptides. 46: 174-85. PMID 7692486 DOI: 10.1016/0167-0115(93)90028-7  0.6
1993 Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 13: 4181-92. PMID 7692009  0.6
1992 Louis DN, Meehan SM, Ferrante RJ, Hedley-Whyte ET. Use of the silver nucleolar organizer region (AgNOR) technique in the differential diagnosis of central nervous system neoplasia. Journal of Neuropathology and Experimental Neurology. 51: 150-7. PMID 1538239  0.6
1991 Ferrante RJ, Kowall NW, Richardson EP. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 11: 3877-87. PMID 1836019  1
1991 Beal MF, Ferrante RJ, Swartz KJ, Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 11: 1649-59. PMID 1710657  1
1990 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ. Homocysteic acid lesions in rat striatum spare somatostatin-neuropeptide Y (NADPH-diaphorase) neurons. Neuroscience Letters. 108: 36-42. PMID 1689475  1
1989 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB. Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions. Synapse (New York, N.Y.). 3: 38-47. PMID 2563916 DOI: 10.1002/syn.890030106  1
1988 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB. Response:Model of Huntington's disease. Science (New York, N.Y.). 241: 475. PMID 17792612 DOI: 10.1126/science.241.4864.475  0.76
1988 Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB. Systemic approaches to modifying quinolinic acid striatal lesions in rats. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 8: 3901-8. PMID 2461437  1
1987 Ferrante RJ, Beal MF, Kowall NW, Richardson EP, Martin JB. Sparing of acetylcholinesterase-containing striatal neurons in Huntington's disease. Brain Research. 411: 162-6. PMID 2955849  1
1987 Ferrante RJ, Kowall NW, Beal MF, Martin JB, Bird ED, Richardson EP. Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington's disease. Journal of Neuropathology and Experimental Neurology. 46: 12-27. PMID 2947977  1
1987 Ferrante RJ, Kowall NW. Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum. Brain Research. 416: 141-6. PMID 2887244  1
1987 Kowall NW, Ferrante RJ, Beal MF, Richardson EP, Sofroniew MV, Cuello AC, Martin JB. Neuropeptide Y, somatostatin, and reduced nicotinamide adenine dinucleotide phosphate diaphorase in the human striatum: a combined immunocytochemical and enzyme histochemical study. Neuroscience. 20: 817-28. PMID 2885780 DOI: 10.1016/0306-4522(87)90242-9  0.6
1986 Ferrante RJ, Kowall NW, Richardson EP, Bird ED, Martin JB. Topography of enkephalin, substance P and acetylcholinesterase staining in Huntington's disease striatum. Neuroscience Letters. 71: 283-8. PMID 2432445  1
1985 Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological classification of Huntington's disease. Journal of Neuropathology and Experimental Neurology. 44: 559-77. PMID 2932539  0.6
1985 Ferrante RJ, Kowall NW, Beal MF, Richardson EP, Bird ED, Martin JB. Selective sparing of a class of striatal neurons in Huntington's disease. Science (New York, N.Y.). 230: 561-3. PMID 2931802  1
1985 Kowall NW, Beal MF, Ferrante RJ, Martin JB. Topography of nicotinamide adenine dinucleotide phosphate-diaphorase staining neurons in rat striatum. Neuroscience Letters. 59: 61-6. PMID 2931630  1
Show low-probability matches.